Theraclone Sciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza
Phase 2
- Conditions
- Influenza
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Theraclone Sciences, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01719874
Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody
Phase 1
Completed
- Conditions
- Cytomegalovirus Infections
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Theraclone Sciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01594437
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza
Phase 1
Completed
- Conditions
- Influenza, Human
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- Theraclone Sciences, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01390025
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
News
No news found